Health Care

Pfizer has won expanded approval from the U.S. Food and Drug Administration of the combination of its Braftovi and Mektovi drugs for patients with metastatic non-small cell lung cancer with a BRAF V600E mutation. The New York drugmaker on Thursday said the approval gives adults with BRAF V600E-mutant metastatic non-small cell lung cancer a new personalized treatment option. Lung cancer is the leading cause of cancer death around the world, with non-small cell lung cancer accounting for more than 80%. A BRAF V600E mutation occurs in roughly 2% of non-small cell lung cancer cases, Pfizer said. The Braftovi/Mektovi combination was previously approved in the U.S. for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Braftovi is also approved in combination with cetuximab for adults with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. Pfizer picked up Braftovi and Mektovi as part of

Pfizer Says Impact Of Tornado On Site Is Expected To Affect Supply Of Medicines From Rocky Mount Facility Until At Least Mid-2024; Begun Storing Non-Production Related Materials In A New Warehouse Secured As A Temporary Replacement To Its Hirise Warehouse